<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00781209</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC - 08 - BC - 270 - CTIL</org_study_id>
    <nct_id>NCT00781209</nct_id>
  </id_info>
  <brief_title>The Role of Posterior Fossa Irradiation (PFI) Plus Stereotactic Radiosurgery (SRS) for Cerebellar Metastases</brief_title>
  <official_title>A Phase II Trial Evaluating the Role of Posterior Fossa Irradiation (PFI) Plus Stereotactic Radiosurgery (SRS) for Cerebellar Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aggregate of data pertaining to brain metastases suggests that optimal results are
      achievable with a 2-pronged approach that addresses both the specific focus (with surgery or
      radiosurgery) and the surrounding brain parenchymal tissue that may harbor micrometastases.
      Patterns of failure following treatment of metastases that arise in the posterior fossa have
      not been reliably defined. Although most would agree that radiosurgery alone is not
      sufficient treatment for focal metastases in the cerebellum, it may be possible to deliver
      less than WBI as an &quot;expanded port&quot; beyond the SRS volume.

      The current study acknowledges that at least two therapeutic modalities are requisite for
      patients with cerebellar metastases but hypothesizes that it is unnecessary to extend the
      treatment of ostensibly uninvolved brain tissue beyond the limits of the posterior fossa. In
      so doing, it is hoped that the putative advantage derived from foregoing whole brain
      irradiation (e.g., reduction in neurocognitive impairment) will not be at the expense of
      excessive surpratentorial failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SCHEMA:

        -  Posterior Fossa Irradiation as defined by diagnostic MRI and CT simulation.

        -  37.5 Gy in 2.5 Gy fractions administered via conformal beams.

        -  Radiosurgical boost (with dose titrated to parameters of RTOG 9005).

        -  Contrast enhanced MRI will be obtained at baseline and then at 3, 6, and 12 months
           following completion of posterior fossa irradiation.

        -  The Mini Mental Status Examination will be used to evaluate global cognitive function at
           baseline and then at 3, 6, and 12 months following completion of posterior fossa
           irradiation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine tumor control rates in the brain following posterior fossa irradiation of patients with cerebellar metastases.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To establish levels of neurocognitive performance following posterior fossa irradiation of patients with cerebellar metastases.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Exp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Posterior Fossa Irradiation 37.5 Gy in 2.5 Gy fractions+Radiosurgical boost; Follow up:Contrast enhanced MRI &amp; Mini Mental Status Examination</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Irradiation plus Stereotactic Radiosurgery</intervention_name>
    <description>Posterior Fossa Irradiation-total dose of 37.5 Gy in 2.5 Gy fractions administered via conformal beams.
Radiosurgical boost-total dose administered to each lesion will be titrated to the size of the metastatic focus as follows:
Maximum Tumor Diameter:&lt;2.0 cm; Assigned Dose:24 Gy. Maximum Tumor Diameter:2.1-3.0 cm;Assigned Dose:18 Gy. Maximum Tumor Diameter:3.1-4.0 cm;Assigned Dose:15 Gy.</description>
    <arm_group_label>Exp</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed malignant disease

          -  All primary tumors exclusive of:

               -  Small cell lung cancer

               -  Renal cell cancer (hypernephroma)

               -  Melanoma

               -  Sarcoma

          -  1-3 intraparenchymal metastases

          -  Age â‰¥18 years

          -  RPA(14) 1 or 2

          -  Patients who have undergone resection are eligible provided residual disease is
             evident on imaging

          -  No clinical or radiographic evidence of progression of extracranial disease in month
             prior to enrollment on study.

        Exclusion Criteria:

          -  Major psychiatric illness

          -  Lesions in brainstem, midbrain, pons, medulla

          -  Patient who have undergone complete resection of all known infratentorial disease

          -  Patients with leptomeningeal metastases

          -  Patients with hepatic metastases

          -  Patients with metastases from the following primary tumors are ineligible: Small Cell
             Lung Cancer; rena Cell Carcinoma; Melanoma; Sarcoma

          -  Previous cranial irradiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben Corn, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiotherapy Department, TASMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ben Corn, Prof.</last_name>
    <phone>972-3-6947285</phone>
    <email>bencorn@tasmc.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radiotherapy Department, TASMC</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marina Gurman</last_name>
      <phone>972-3-6974098</phone>
      <email>marinag@tasmc.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Vika Gurevich</last_name>
      <phone>972-3-6947285</phone>
      <email>vikag@tasmc.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Kanner, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deborah Blumenthal, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix Bokstein, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2008</study_first_submitted>
  <study_first_submitted_qc>October 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2008</study_first_posted>
  <last_update_submitted>October 27, 2008</last_update_submitted>
  <last_update_submitted_qc>October 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Ben Corn</name_title>
    <organization>Radiotherapy Department, TASMC</organization>
  </responsible_party>
  <keyword>irradiation</keyword>
  <keyword>stereotactic radiosurgery</keyword>
  <keyword>posterior fossa</keyword>
  <keyword>cerebellar metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

